All In Biotech

Investigational drug · Phase 3

Lerotinib

Also called: Z650

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Esophageal Cancer.

Phase 3

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "Lerotinib"

First trial start

2021

Jan 21, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Lerotinib", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Esophageal Cancer

Approved drugs for the same conditions: Stomach and esophageal cancer · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "Lerotinib" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Esophageal Cancer

  • Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma

  • Tegafur-gimeracil-oteracil potassiumS-1, tegafurPhase 38 trials

    Ono Pharmaceutical Co., Ltd. · Gastric Cancer, Esophageal Cancer, Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

  • AZD0901Sonesitatug vedotin, CMG901Phase 36 trials

    AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma

  • PetosemtamabMCLA-158, GEN1158Phase 35 trials

    Genmab · Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Advanced/Metastatic Solid Tumors

  • [18F]FAPI-74 PETPhase 33 trials

    SOFIE · Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction

  • SI-B003Phase 210 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck

  • TQB6411Phase 22 trials

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Advanced Lung Cancer, Esophageal Cancer

  • IMT-009Phase 21 trial

    Immunitas Therapeutics · Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.